Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
CRBU Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Caribou Biosciences, Inc.NASDAQ: CRBU
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$26.28M, compared with -$42.91M a year earlier. Trailing-twelve-month operating income was -$131.71M.
Context
- Operating income amounted to 1220.5% of revenue in FY2025, down 446.7 pp from a year earlier.
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 4 analysts of -$83.3M (+38.8%) for the fiscal year ending Dec 2026, a step up from the +18.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$26.28M+7.6% QoQ
- Last fiscal yearDec 2025
- -$136.19M+18.3% YoY
- LTMMar 2026
- -$131.71M+19.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +38.8% | +31.2% | -7.5 pp |
| 1 year | +18.3% | +38.8% | +20.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (136.19M) USD
- Year-over-year change
- +18.3%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (136.19M) | +18.3% |
| FY2024 | 2024-12-31 | (166.62M) | -43.6% |
| FY2023 | 2023-12-31 | (116.06M) | -9.1% |
| FY2022 | 2022-12-31 | (106.4M) | -58.9% |
| FY2021 | 2021-12-31 | (66.98M) | — |
Operating Income vs competitors
How CRBU compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +19.5% is the 7th highest of 11, against a peer median of +19.8%.
- Operating income amounts to 1175.7% of revenue for CRBU, versus a peer median of 561.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$54.96M USD | +20.1% | — | 168.0% | |
| LTM Mar 2026 | -$60.38M USD | +40.9% | — | 87.2% | |
| LTM Mar 2026 | -$74.72M USD | -140.4% | — | — | |
| LTM Mar 2026 | -$80.77M USD | +17.1% | — | 286.2% | |
| LTM Mar 2026 | -$84.14M USD | +39.9% | — | 503.2% | |
| LTM Mar 2026 | -$85.86M USD | +21.8% | — | 38159.1% | |
| LTM Mar 2026 | -$85.87M USD | +19.6% | — | 619.6% | |
| LTM Mar 2026 | -$113.89M USD | -2.6% | — | 5649.2% | |
| FY2025 | -€130.95M EUR | -34.2% | — | 2921.0% | |
| LTM Mar 2026 | -$131.71M USD | +19.5% | — | 1175.7% | |
| LTM Mar 2026 | -$190.22M USD | +29.3% | — | — | |
| Peer median (excluding CRBU) | — | +19.8% | — | 561.4% | |
Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.6M | 13.85M | 34.48M | 9.99M | 11.16M |
| Cost of Revenue | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| Gross Profit | 8.61M | 10.21M | 30.95M | 6.07M | 7.51M |
| Gross Margin | 89.7% | 73.7% | 89.8% | 60.7% | 67.3% |
| Research & Development | 52.26M | 82.23M | 112.08M | 130.15M | 109.44M |
| Selling, General & Admin | 23.34M | 38.02M | 38.46M | 46.46M | 37.91M |
| Operating Expenses | 75.59M | 116.61M | 147.01M | 172.68M | 143.71M |
| Depreciation & Amortization | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| EBITDA | (65.61M) | (95.71M) | (98.35M) | (145.19M) | (145.03M) |
| EBITDA Margin | -683.6% | -691.0% | -285.3% | -1452.7% | -1299.7% |
| Operating Income | (66.98M) | (106.4M) | (116.06M) | (166.62M) | (136.19M) |
| Operating Margin | -697.8% | -768.2% | -336.6% | -1667.2% | -1220.5% |
| Interest Income | 148K | 4.6M | 10.7M | 0 | 8M |
| Interest Expense | 8K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 377K | 7.05M | 14.18M | 17.5M | (12.48M) |
| Income Before Tax | (66.6M) | (99.35M) | (101.88M) | (149.11M) | (148.68M) |
| Pre-Tax Margin | -693.9% | -717.3% | -295.5% | -1492.0% | -1332.3% |
| Income Tax Expense | 321K | 70K | 193K | (9K) | (550K) |
| Net Income | (66.92M) | (99.42M) | (102.07M) | (149.11M) | (148.13M) |
| Net Margin | -697.3% | -717.8% | -296.1% | -1491.9% | -1327.4% |
| EPS (Basic) | (1.11) | (1.64) | (1.38) | (1.65) | (1.59) |
| EPS (Diluted) | (1.11) | (1.64) | (1.38) | (1.65) | (1.59) |
| Weighted Avg Shares | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M |
| Weighted Avg Shares (Diluted) | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M |
Caribou Biosciences, Inc.
NASDAQ:CRBU
Intrinsic Alpha fair value
Locked
Current Price
$0.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.